Other SAEs in the fingolimod group included single cases (0.9%) of agranulocytosis, arthralgia, autoimmune uveitis, bladder spasm, dyspepsia, dysuria, elevated alanine aminotransferase level, elevated γ-glutamyl transferase level, gastrointestinal necrosis (intussusception or necrotic bowel), head injury, humerus fracture, hypersensitivity vasculitis, migraine, migraine without aura, muscular weakness, rectal tenesmus, second-degree atrioventricular block, and small-intestinal obstruction and two cases of leukopenia (1.9%). The gene discussed is GPT; the disease is migraine disorder.